Engineering immunity via skin-directed drug delivery devices. 2022

Suryanarayana Polaka, and Vaishali Makwana, and Nupur Vasdev, and Anjani Sheth, and Kuldeep Rajpoot, and Pinaki Sengupta, and Rakesh Kumar Tekade
National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opp. Air force station, Gandhinagar 382355, Gujarat, India.

Extensive research is underway to discover a safe and effective vehicle to deliver the vaccines at the desired cutaneous site. These efforts majorly comprise the development of a fit-to-purpose vehicle for in-situ intracutaneous vaccine delivery for achieving the systemic cellular and humoral response to combat infectious diseases. Advancements in nanoscience, bioengineering, and skin science provided much support to vaccine adjuvant development. However, the bench-to-bed side translation of vaccines is still unsatisfactory. A skilfully designed vaccine delivery program aiming to translate the product into market use must address safety, efficacy, scaleup, reproducibility, cost of production, self-administrative potential, and regulatory concerns. This review provides deep insights into skin immunization approaches like mucosal vaccines, cellular/molecular immunological responses, and antigen-adjuvant combinations in modulating immunity. Further, the manuscript discusses distinct vaccine delivery systems used to date for engineering skin immunization, including microparticles, nanoparticles, spherical nucleic acids, STAR particles, niosomes, dendrimers, ethosomes, liposomes, and microneedles. The manuscript will interest researchers working towards developing a next-generation fit-to-purpose vehicle for intracutaneous vaccine delivery.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D014612 Vaccines Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases. Vaccine
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D053758 Nanoparticles Nanometer-sized particles that are nanoscale in three dimensions. They include nanocrystaline materials; NANOCAPSULES; METAL NANOPARTICLES; DENDRIMERS, and QUANTUM DOTS. The uses of nanoparticles include DRUG DELIVERY SYSTEMS and cancer targeting and imaging. Nanocrystalline Materials,Nanocrystals,Material, Nanocrystalline,Materials, Nanocrystalline,Nanocrystal,Nanocrystalline Material,Nanoparticle
D018928 Immunity, Mucosal Nonsusceptibility to the pathogenic effects of foreign microorganisms or antigenic substances as a result of antibody secretions of the mucous membranes. Mucosal epithelia in the gastrointestinal, respiratory, and reproductive tracts produce a form of IgA (IMMUNOGLOBULIN A, SECRETORY) that serves to protect these ports of entry into the body. Immune Response, Mucosal,Mucosal Immunity,Immune Responses, Mucosal,Mucosal Immune Response,Mucosal Immune Responses

Related Publications

Suryanarayana Polaka, and Vaishali Makwana, and Nupur Vasdev, and Anjani Sheth, and Kuldeep Rajpoot, and Pinaki Sengupta, and Rakesh Kumar Tekade
December 2004, Lung cancer (Amsterdam, Netherlands),
Suryanarayana Polaka, and Vaishali Makwana, and Nupur Vasdev, and Anjani Sheth, and Kuldeep Rajpoot, and Pinaki Sengupta, and Rakesh Kumar Tekade
January 2008, Methods in molecular biology (Clifton, N.J.),
Suryanarayana Polaka, and Vaishali Makwana, and Nupur Vasdev, and Anjani Sheth, and Kuldeep Rajpoot, and Pinaki Sengupta, and Rakesh Kumar Tekade
September 2014, Journal of controlled release : official journal of the Controlled Release Society,
Suryanarayana Polaka, and Vaishali Makwana, and Nupur Vasdev, and Anjani Sheth, and Kuldeep Rajpoot, and Pinaki Sengupta, and Rakesh Kumar Tekade
June 2021, Advanced science (Weinheim, Baden-Wurttemberg, Germany),
Suryanarayana Polaka, and Vaishali Makwana, and Nupur Vasdev, and Anjani Sheth, and Kuldeep Rajpoot, and Pinaki Sengupta, and Rakesh Kumar Tekade
March 2022, AAPS PharmSciTech,
Suryanarayana Polaka, and Vaishali Makwana, and Nupur Vasdev, and Anjani Sheth, and Kuldeep Rajpoot, and Pinaki Sengupta, and Rakesh Kumar Tekade
March 2015, Expert opinion on drug delivery,
Suryanarayana Polaka, and Vaishali Makwana, and Nupur Vasdev, and Anjani Sheth, and Kuldeep Rajpoot, and Pinaki Sengupta, and Rakesh Kumar Tekade
June 2017, Annual review of chemical and biomolecular engineering,
Suryanarayana Polaka, and Vaishali Makwana, and Nupur Vasdev, and Anjani Sheth, and Kuldeep Rajpoot, and Pinaki Sengupta, and Rakesh Kumar Tekade
March 2017, Journal of controlled release : official journal of the Controlled Release Society,
Suryanarayana Polaka, and Vaishali Makwana, and Nupur Vasdev, and Anjani Sheth, and Kuldeep Rajpoot, and Pinaki Sengupta, and Rakesh Kumar Tekade
September 2006, Current drug discovery technologies,
Suryanarayana Polaka, and Vaishali Makwana, and Nupur Vasdev, and Anjani Sheth, and Kuldeep Rajpoot, and Pinaki Sengupta, and Rakesh Kumar Tekade
December 2007, Current pharmaceutical biotechnology,
Copied contents to your clipboard!